Published in Biol Blood Marrow Transplant on January 01, 2001
Induction of Stable Chimerism for Sickle Cell Anemia | NCT00029393
Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med (2009) 4.59
Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA (2014) 2.01
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood (2015) 2.00
Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood (2011) 1.90
Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat Biotechnol (2016) 1.64
Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant (2009) 1.46
Correction of murine hemoglobinopathies by prenatal tolerance induction and postnatal nonmyeloablative allogeneic BM transplants. Blood (2015) 1.42
Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica (2010) 1.32
Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood (2005) 1.31
Transplantation immunology: solid organ and bone marrow. J Allergy Clin Immunol (2010) 1.30
β-globin gene transfer to human bone marrow for sickle cell disease. J Clin Invest (2013) 1.22
Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant (2012) 1.21
Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med (2012) 1.18
A Child as a Donor for Hematopoietic Stem Cell Transplantation: Bioethical Justification-A Case Study on Sickle Cell Disease. Case Rep Hematol (2017) 1.06
Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Exp Hematol (2006) 1.03
Gene therapy for hemoglobinopathies: the state of the field and the future. Hematol Oncol Clin North Am (2014) 0.94
Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant (2013) 0.92
Sirolimus and post transplant Cy synergistically maintain mixed chimerism in a mismatched murine model. Bone Marrow Transplant (2013) 0.91
In mixed hematopoietic chimerism, the donor red cells win. Haematologica (2011) 0.91
In utero depletion of fetal hematopoietic stem cells improves engraftment after neonatal transplantation in mice. Blood (2014) 0.90
RH genotyping in a sickle cell disease patient contributing to hematopoietic stem cell transplantation donor selection and management. Blood (2010) 0.87
Relationship between mixed chimerism and rejection after bone marrow transplantation in thalassaemia. Blood Transfus (2008) 0.87
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood (2016) 0.86
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant (2014) 0.85
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene. Hum Gene Ther (2016) 0.85
Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants. Stem Cells Transl Med (2013) 0.85
A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases. Biol Blood Marrow Transplant (2013) 0.84
Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. Biol Blood Marrow Transplant (2013) 0.84
Sickle cell diseases: current therapeutic options and potential pitfalls in preventive therapy for transcranial Doppler abnormalities. Pediatr Radiol (2005) 0.83
Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions. Ther Adv Hematol (2013) 0.83
Severe sickle cell disease--pathophysiology and therapy. Biol Blood Marrow Transplant (2009) 0.83
Hematopoietic Stem Cell Transplantation in Adult Sickle Cell Disease: Problems and Solutions. Turk J Haematol (2015) 0.82
Hematopietic stem cell transplantation in thalassemia and related disorders. Mediterr J Hematol Infect Dis (2009) 0.82
Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacement. Immunol Allergy Clin North Am (2010) 0.82
Use of genome-editing tools to treat sickle cell disease. Hum Genet (2016) 0.82
Late effects of myeloablative bone marrow transplantation (BMT) in sickle cell disease (SCD). Blood (2008) 0.81
Hematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerations. J Blood Med (2015) 0.81
Barriers to hematopoietic cell transplantation clinical trial participation of african american and black youth with sickle cell disease and their parents. J Pediatr Hematol Oncol (2013) 0.81
Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease. Am J Hematol (2016) 0.81
Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacement. Hematol Oncol Clin North Am (2011) 0.80
Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J Clin Invest (2016) 0.80
Early CD3+/CD15+ peripheral blood leukocyte chimerism patterns correlate with long-term engraftment in non-malignant hematopoietic SCT. Bone Marrow Transplant (2014) 0.77
Gene Therapy for Hemoglobinopathies: Tremendous Successes and Remaining Caveats. Mol Ther (2016) 0.77
Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions. Hematol Oncol Clin North Am (2014) 0.77
Tolerance after solid organ and hematopoietic cell transplantation. Biol Blood Marrow Transplant (2012) 0.77
Normalization of red cell enolase level following allogeneic bone marrow transplantation in a child with Diamond-Blackfan anemia. J Korean Med Sci (2010) 0.75
Peripheral red blood cell split chimerism as a consequence of intramedullary selective apoptosis of recipient red blood cells in a case of sickle cell disease. Mediterr J Hematol Infect Dis (2014) 0.75
Treosulfan-Based Conditioning Regimen in Sibling and Alternative Donor Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease. Mediterr J Hematol Infect Dis (2017) 0.75
The role of donor-derived veto cells in nonmyeloablative haploidentical HSCT. Bone Marrow Transplant (2015) 0.75
Gene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow's Point of View. Stem Cells Dev (2016) 0.75
A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood (2016) 0.75
Alternative donor transplant of benign primary hematologic disorders. Bone Marrow Transplant (2015) 0.75
Gene Therapy for β-Hemoglobinopathies. Mol Ther (2017) 0.75
Awareness, Knowledge, and Acceptance of Haematopoietic Stem Cell Transplantation for Sickle Cell Anaemia in Nigeria. Bone Marrow Res (2016) 0.75
Gene therapy for hemoglobin disorders - a mini-review. J Rare Dis Res Treat (2016) 0.75
Nonchromosomal antibiotic resistance in bacteria: genetic transformation of Escherichia coli by R-factor DNA. Proc Natl Acad Sci U S A (1972) 57.06
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Pain in sickle cell disease. Rates and risk factors. N Engl J Med (1991) 9.75
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64
Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med (1998) 7.07
Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med (1998) 6.88
Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challenges. Am J Bioeth (2009) 6.13
Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med (1986) 5.84
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med (2001) 5.14
Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science (1995) 4.80
Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood (2001) 4.22
Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood (1995) 4.18
Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11
Bone marrow transplantation for sickle cell disease. N Engl J Med (1996) 4.02
HIV quasispecies and resampling. Science (1996) 3.98
Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med (2001) 3.98
Mortality rates in displaced and resident populations of central Somalia during 1992 famine. Lancet (1993) 3.84
Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis (1997) 3.67
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59
Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol (1993) 3.41
Bone-marrow transplantation (first of two parts). N Engl J Med (1975) 3.33
Plasma homocysteine levels and folate status in children with sickle cell anemia. J Pediatr Hematol Oncol (1999) 3.27
Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med (1994) 3.26
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med (1986) 3.22
High-dose intravenous methylprednisolone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med (1994) 3.10
Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol Infect (1993) 3.06
Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med (1998) 3.04
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc (1974) 2.95
Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am (1999) 2.86
Experimental investigation of geologically produced antineutrinos with KamLAND. Nature (2005) 2.75
The canine major histocompatibility complex. Supertypic specificities defined by the primed lymphocyte test (PLT). Immunogenetics (1984) 2.72
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol (2009) 2.71
Sequence analysis using logic regression. Genet Epidemiol (2001) 2.69
Project normal: defining normal variance in mouse gene expression. Proc Natl Acad Sci U S A (2001) 2.66
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
The application of mitochondrial DNA typing to the study of white Caucasian genetic identification. Int J Legal Med (1993) 2.64
Regression calibration in failure time regression. Biometrics (1997) 2.61
Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med (1981) 2.61
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood (1999) 2.59
Clinical and neuroradiographic manifestations of eastern equine encephalitis. N Engl J Med (1997) 2.55
The load dependence of kinesin's mechanical cycle. Proc Natl Acad Sci U S A (1997) 2.50
Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost (2015) 2.46
Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma. Proc Natl Acad Sci U S A (1989) 2.45
Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med (1992) 2.42
Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med (1989) 2.42
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36
Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med (1998) 2.36
Immune response after splenectomy. Lancet (1978) 2.31
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood (1996) 2.30
Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med (1985) 2.30
A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood (1993) 2.29
Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29
Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci U S A (1989) 2.23
A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr (2001) 2.22
Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med (1988) 2.19
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14
Does cholesterol screening result in negative labeling effects? Results of the Massachusetts Model Systems for Blood Cholesterol Screening Project. Arch Intern Med (1991) 2.14
Ethical aspects of banking placental blood for transplantation. JAMA (1995) 2.07
The acute chest syndrome of sickle cell disease. J Pediatr (1999) 2.04
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Successful therapy for trilateral retinoblastoma. Am J Ophthalmol (1992) 2.03
Human CD1d-glycolipid tetramers generated by in vitro oxidative refolding chromatography. Proc Natl Acad Sci U S A (2001) 1.99
Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology (2001) 1.98
The pediatrician and cancer prevention. Accepting the present, changing the future. Arch Pediatr Adolesc Med (1995) 1.98
Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology (1998) 1.92
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol (2000) 1.92
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92
Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol (1990) 1.91
The Washington State Intergenerational Study of Birth Outcomes: methodology and some comparisons of maternal birthweight and infant birthweight and gestation in four ethnic groups. Paediatr Perinat Epidemiol (1999) 1.90
Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med (1983) 1.89
Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J Infect Dis (2000) 1.87
Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med (1982) 1.85
Serotype-specific immunoglobulin G antibody responses to pneumococcal polysaccharide vaccine in children with sickle cell anemia: effects of continued penicillin prophylaxis. J Pediatr (1996) 1.84
Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood (2000) 1.84
A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood (1979) 1.83